These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 22405187)

  • 41. Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations.
    de Bruin MA; Kwong A; Goldstein BA; Lipson JA; Ikeda DM; McPherson L; Sharma B; Kardashian A; Schackmann E; Kingham KE; Mills MA; West DW; Ford JM; Kurian AW
    Fam Cancer; 2012 Sep; 11(3):429-39. PubMed ID: 22638769
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recommendations of Health Care Professionals on the Issue of Breastfeeding in BRCA Carriers.
    Echar M; Singer A; Lena SD
    Breastfeed Med; 2024 Jul; 19(7):534-538. PubMed ID: 38853719
    [No Abstract]   [Full Text] [Related]  

  • 43. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
    J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Lynch HT; Ghadirian P; Tung N; Kim-Sing C; Olopade OI; Domchek S; Eisen A; Foulkes WD; Rosen B; Vesprini D; Sun P; Narod SA
    Breast Cancer Res Treat; 2011 May; 127(1):287-96. PubMed ID: 21221768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Gronwald J; Lynch HT; Eisen A; Neuhausen SL; Tung N; Ainsworth P; Weitzel JN; Pal T; Foulkes WD; Eng C; Singer CF; Senter L; Sun P; Lubinski J; Narod SA;
    Breast Cancer Res Treat; 2018 Sep; 171(2):421-426. PubMed ID: 29774471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
    Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
    Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
    Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
    Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
    J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients.
    Jouhadi H; Tazzite A; Azeddoug H; Naim A; Nadifi S; Benider A
    BMC Res Notes; 2016 Apr; 9():248. PubMed ID: 27129401
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.
    Kotsopoulos J; Lubinski J; Moller P; Lynch HT; Singer CF; Eng C; Neuhausen SL; Karlan B; Kim-Sing C; Huzarski T; Gronwald J; McCuaig J; Senter L; Tung N; Ghadirian P; Eisen A; Gilchrist D; Blum JL; Zakalik D; Pal T; Sun P; Narod SA;
    Breast Cancer Res Treat; 2014 Feb; 143(3):579-86. PubMed ID: 24458845
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update.
    Ginsburg O; Ghadirian P; Lubinski J; Cybulski C; Lynch H; Neuhausen S; Kim-Sing C; Robson M; Domchek S; Isaacs C; Klijn J; Armel S; Foulkes WD; Tung N; Moller P; Sun P; Narod SA;
    Breast Cancer Res Treat; 2009 Mar; 114(1):127-35. PubMed ID: 18483851
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS).
    Andrieu N; Goldgar DE; Easton DF; Rookus M; Brohet R; Antoniou AC; Peock S; Evans G; Eccles D; Douglas F; Noguès C; Gauthier-Villars M; Chompret A; Van Leeuwen FE; Kluijt I; Benitez J; Arver B; Olah E; Chang-Claude J; ; ; ;
    J Natl Cancer Inst; 2006 Apr; 98(8):535-44. PubMed ID: 16622123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.
    Lee YC; Milne RL; Lheureux S; Friedlander M; McLachlan SA; Martin KL; Bernardini MQ; Smith C; Picken S; Nesci S; Hopper JL; Phillips KA;
    Eur J Cancer; 2017 Oct; 84():114-120. PubMed ID: 28802188
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
    Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers.
    Stjepanovic N; Lubinski J; Moller P; Randall Armel S; Foulkes WD; Tung N; Neuhausen SL; Kotsopoulos J; Sun P; Sun S; Eisen A; Narod SA;
    Breast Cancer Res Treat; 2021 Jun; 187(2):515-523. PubMed ID: 33423179
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
    Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.